Structure via PubChem · Public domain (PubChem)
naloxegol
Sign in to saveAlso known as AZ-13337019, AZ13337019, Movantik®, NKTR-118, NKTR 118, NKTR118
Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia.
Key facts
- Drug.image
- Naloxegol.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Movantik, Moventig
- Drug.DailyMedID
- Naloxegol
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A06
- Drug.ATC_suffix
- AH03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx only
- Drug.legal_EU
- Rx only
- Drug.CAS_number
- 854601-70-0
- Drug.PubChem
- 56959087
- Drug.ChemSpiderID
- 28651656
- Drug.ChEBI
- 82975
- Drug.UNII
- 44T7335BKE
- Drug.KEGG
- D10479
- Drug.IUPAC_name
- (5α,6α)-4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)morphinan-3,14-diol
via Wikipedia infobox
Chemical data
- Formula
- C34H53NO11
- Molecular weight
- 651.8 g/mol
- IUPAC name
- (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
- SMILES
- COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O
- InChIKey
- XNKCCCKFOQNXKV-ZRSCBOBOSA-N
- XLogP
- -1
- Polar surface area
- 127 Ų
- H-bond donors
- 2
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- oral
- Indications
- Constipation, opioid dependence, non-small cell lung carcinoma, ileus
via ChEMBL · EBI
Research
180 papers- PMID 408573662025
- Naloxegol.2006
- Naloxegol.2012
- Evaluating naloxegol for the treatment of opioid-induced constipation.Expert opinion on pharmacotherapy · 2020
- PMID 408573652025
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 651.361862
- Has use
- medication
Show 7 more facts
- chemical formula
- C₃₄H₅₃NO₁₁
- canonical SMILES
- COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O
- isomeric SMILES
- COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O
- World Health Organisation international non-proprietary name
- naloxegol
- defined daily dose
- 25
- subject has role
- opioid antagonist
- medical condition treated
- constipation
via Wikidata · CC0
~3 min read
Encyclopedic overview
5 sectionsContents
- Medical use
- Side effects
- Pharmacodynamic properties
- Mechanism of action
- References
Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia.
The most common side effects are abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache.
Excerpted from Wikipedia’s “naloxegol” article, available under the CC BY-SA 4.0 licence.